Cargando…
Use of Patient-Derived Organoids as a Treatment Selection Model for Colorectal Cancer: A Narrative Review
SIMPLE SUMMARY: Colorectal cancer (CRC) is the third most common type of cancer globally. Despite successful treatment, it has a 40% chance of recurrence within five years after surgery. While neoadjuvant chemotherapy is offered for stage IV cancers, it comes with a risk of resistance and disease pr...
Autores principales: | Furbo, Sara, Urbano, Paulo César Martins, Raskov, Hans Henrik, Troelsen, Jesper Thorvald, Kanstrup Fiehn, Anne-Marie, Gögenur, Ismail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870458/ https://www.ncbi.nlm.nih.gov/pubmed/35205817 http://dx.doi.org/10.3390/cancers14041069 |
Ejemplares similares
-
The VTI1A-TCF4 colon cancer fusion protein is a dominant negative regulator of Wnt signaling and is transcriptionally regulated by intestinal homeodomain factor CDX2
por: Davidsen, Johanne, et al.
Publicado: (2018) -
Bacterial biofilm formation inside colonic crypts may accelerate colorectal carcinogenesis
por: Raskov, Hans, et al.
Publicado: (2018) -
Development of a method for digital assessment of tumor regression grade in patients with rectal cancer following neoadjuvant therapy
por: Jepsen, Dea Natalie Munch, et al.
Publicado: (2022) -
Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy
por: Raskov, Hans, et al.
Publicado: (2022) -
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
por: Raskov, Hans, et al.
Publicado: (2021)